TargetMol

Velaresol

Product Code:
 
TAR-T35044
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T35044-100mg100mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35044-50mg50mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Velaresol (BW12C, BW12C79) is an oxygenated hemoglobin stabilizer that, in addition to stabilizing oxygenated hemoglobin, protects sickle cells from calcium-mediated dehydration.
CAS:
77858-21-0
Formula:
C12H14O5
Molecular Weight:
238.239
Purity:
0.98
SMILES:
OC(=O)CCCCOc1cccc(O)c1C=O

References

Gibson JS, Khan A, Speake PF, Ellory JC. O2 dependence of K+ transport in sickle cells: the effect of different cell populations and the substituted benzaldehyde 12C79. FASEB J. 2001 Mar;15(3):823-32. PubMed PMID: 11259401. Trudel M, De Paepe ME, Chr?tien N, Saadane N, Jacmain J, Sorette M, Hoang T, Beuzard Y. Sickle cell disease of transgenic SAD mice. Blood. 1994 Nov 1;84(9):3189-97. PubMed PMID: 7949191. Propper DJ, Levitt NC, O'Byrne K, Braybrooke JP, Talbot DC, Ganesan TS, Thompson CH, Rajagopalan B, Littlewood TJ, Dixon RM, Harris AL. Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. Br J Cancer. 2000 Jun;82(11):1776-82. PubMed PMID: 10839290; PubMed Central PMCID: PMC2363221. Philip PA, Thompson CH, Carmichael J, Rea D, Mitchell K, Taylor DJ, Stuart NS, Dennis I, Rajagopalan B, Ganesan T, et al. A phase I study of the left-shifting agent BW12C79 plus mitomycin C and the effect on the skeletal muscle metabolism using 31P magnetic resonance spectroscopy. Cancer Res. 1993 Dec 1;53(23):5649-53. PubMed PMID: 8242619.